ZBH · Zimmer Biomet Holdings, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Zimmer Biomet raised full-year 2026 organic constant currency revenue guidance to 2.25%-3.25% (from 1%-3%) and adjusted EPS guidance to $8.47-$8.59 (from $8.40-$8.55), and increased its 2026 share repurchase plan by $250 million to up to $1 billion, following Q2 organic constant currency revenue growth of 4.0%, Hips up 5.1% and Technology & Data up 21.5%, though adjusted operating margin contracted 210 bps year-over-year to 25.7%.
- + Raised full-year 2026 organic constant currency revenue guidance to 2.25%-3.25% from 1%-3%
- + Raised full-year 2026 adjusted EPS guidance to $8.47-$8.59 from $8.40-$8.55
- + Increased 2026 share repurchase plan by $250 million to up to $1 billion
- + Hips grew 5.1% constant currency, including 5.9% in the U.S., driven by the Z1/HEMER/OrthoGrid 'HIP triple play'
- + Technology & Data, Bone Cement and Surgical grew 21.5%, with U.S. technology sales up 53% and new ROSA Shoulder launch underway
- − Adjusted operating margin contracted 210 bps year-over-year to 25.7% in Q2, with full-year operating margins now expected to decline a little more than 50 bps
- − Adjusted gross margin declined 120 bps year-over-year to 71.1% on increased manufacturing costs
- − Pricing was an 80 bps headwind in the quarter within the full-year range of up to 100 bps
- − Knees grew only 0.1% organically with international down 1.5% on China and emerging market pressures; management flagged China declining 20% this year
- − Adjusted EPS of $2.07 was flat year-over-year despite higher revenue due to Paragon 28 dilution and U.S. commercial investments
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZBH
this stock
Zimmer Biomet Holdings, Inc.
|
$17.32B | +1.6% | +7.2% | 22.0 | 4.5% |
|
ABT
Abbott Laboratories
|
$174.90B | -19.4% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -9.3% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -20.7% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.0% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZBH | -2.8% | -8.7% | -1.8% | -8.7% | +1.6% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -1.6% | -8.3% | -14.9% | -8.3% | -10.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.